AI Strategy Index

AstraZeneca AI Strategy: 17,000 Certified Employees and 1,000 Pilots

How AstraZeneca uses AI on its own work: AI certification for more than 17,000 employees, about 1,000 pilots and AI in cancer research. Updated November 2026.

Company
AstraZeneca
Industry
Healthcare & pharma
Headquarters
Cambridge, United Kingdom
Region
Europe
AI strategy
Inferred from public sources
Index group
STOXX Europe 50

UK-based biopharmaceutical company in oncology, rare diseases, and cardiovascular, renal, metabolic and respiratory medicines

Where the AI strategy is set out

AstraZeneca has published no AI strategy for its own work. This profile is inferred from its finance chief’s 2026 interviews, a company article and deal announcements.

Read the company source

Where AstraZeneca Is Going with AI

AstraZeneca is building AI skills at scale while it works toward $80bn in revenue by 2030. Chief Financial Officer Aradhana Sarin told Fortune in April 2026 that more than 17,000 employees had been certified in AI. She said: “I think people are really embracing AI and learning and developing their own skills.”

AstraZeneca has published no AI strategy for its own work. This profile is inferred from its finance chief’s 2026 interviews, a company article and deal announcements.

The focus has four parts.

  • Skills: a Bronze, Silver and Gold certification framework for AI
  • Pilots: about 1,000 active AI pilots, with generative and agentic AI under exploration
  • Oncology research: the foundation models and agentic AI platform of Modella AI, which AstraZeneca agreed to acquire in January 2026
  • Finance: a review of which pilots merit resources to scale, based on expected impact

What It Takes: Certification, Pilot Selection and Acquired AI

Certification is required for senior staff. Staff above a certain grade must reach at least the Silver level, Fortune reported. More than 12,000 employees had joined the upskilling program by April 2025, according to an AstraZeneca article.

A woman in profile with digital network graphics around her head beside a mulberry panel
The banner AstraZeneca used for its April 2025 article on upskilling its workforce for the age of AI. Image: AstraZeneca

The program aims at speed and scale. Cindy Hoots, Chief Digital Officer and CIO at the time, said in that article: “By upskilling our employees in AI at speed and scale, we’re future-proofing our workforce.”

Finance decides which pilots scale. AstraZeneca runs about 1,000 pilots, close to the thousand-experiments approach to AI strategy, and finance helps pick the ones that merit resources. Sarin said: “You need to figure out which ones will truly move the needle.”

AstraZeneca is buying AI capability for cancer research. Modella AI’s models combine pathology, imaging and other biomarker data to automate data-intensive work, according to American Pharmaceutical Review. Modella will operate from Boston inside AstraZeneca’s oncology organization.

AstraZeneca does not expect AI to cut staff. Sarin said in July 2026 that AI is not expected to lead to staff reductions, according to Placera. Headcount rose 15% from 2022 to 2025, to about 96,100.

AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):

  • Fluency floor: Not published for all staff. Staff above a set grade must reach Silver, and AstraZeneca has not said what share of staff that covers.
  • Highest level evidenced: Level 2 (Collaborating), company-claimed. Certified staff use AI in their own work and about 1,000 pilots run. AstraZeneca has published few results of AI built into workflows at scale.
  • Portfolio design: AstraZeneca runs many pilots, lets finance pick which ones scale and buys AI capability for oncology research.

How AstraZeneca Measures Results

AstraZeneca reports AI skills and activity, without value figures. The figures below are company-claimed:

  • Certification: more than 17,000 employees certified in AI by April 2026
  • Upskilling: more than 12,000 participants by April 2025
  • Pilots: about 1,000 active

Gaps remain. Sarin said: “The value capture happens when you convert those pilots into production and really embed that in the workflow.” AstraZeneca has not reported how many pilots reached production, and reporting that is the step from AI adoption to AI value.

Next markers: pilots moved into production, results from Modella in oncology research, the share of staff at Silver and headcount for 2026.

Change log

  • April 2025: AstraZeneca reports more than 12,000 employees in its AI upskilling program.
  • January 2026: AstraZeneca agrees to acquire Modella AI.
  • April 2026: Sarin reports more than 17,000 AI-certified employees and about 1,000 pilots.
  • July 2026: Sarin says AI is not expected to lead to staff reductions.

The Bottom Line

  • Disclosure: 4 of 4. AstraZeneca answers all four questions, the last in part, through finance’s review of pilots and without value figures.
  • AI certification is required above a set grade.
  • About 1,000 pilots compete to scale.
  • Level 2 is evidenced across the workforce, on company-claimed figures.
  • The say-do gap is scale. Value depends on moving pilots into production, and AstraZeneca has not reported how many have moved.
  • Watch Modella. The test is whether acquired AI speeds up oncology research.

Revenue, Headcount and Revenue per Employee

What the numbers show: Total revenue rose 32% from 2022 to 2025 while headcount rose 15%, so revenue per employee rose 15%, to about $611k. AstraZeneca targets $80bn in revenue by 2030. These figures do not show that AI caused any change.

Revenue, headcount and revenue per employee, FY2022 to FY2025

  • FY2022: $44.35bn revenue, 83,500 employees, $531k per employee
  • FY2023: $45.81bn revenue, 89,900 employees, $510k per employee
  • FY2024: $54.07bn revenue, 94,300 employees, $573k per employee
  • FY2025: $58.74bn revenue, 96,100 employees, $611k per employee

Change, FY2022 to FY2025: revenue up 32%, headcount up 15%, revenue per employee up 15%.

Notes: Revenue is total revenue, as reported. Headcount is approximate, at year-end.

These figures give context on scale and productivity. They do not show that AI caused any change. Sources: AstraZeneca 20-F filings.

How AstraZeneca Compares with European Pharma Peers

We looked at how AstraZeneca compares with other European pharmaceutical companies in the index. Here is how they stack up.

CompanyDisclosureAI ownerFluency floorGovernanceAI value reportedRevenue per employee
AstraZeneca4 of 4No single owner named; finance picks pilots to scaleNot published; Silver certification above a set gradeFinance reviews which pilots scaleNo: certifications and pilots only$611k
GSK3 of 4SVP Global Head of AI and Machine LearningNot publishedLittle publishedNo: savings plan with no AI share$631k
Novartis2 of 4CIO; no Chief AI OfficerRole-based paths, no company-wide floorPublished, a standing board topicLinked to lower costs, no figure$725k
Novo Nordisk4 of 4CEO-led OpenAI partnershipNot published; OpenAI to build AI fluencyData governance and human oversight, statedResults by use case, no total$680k
Roche4 of 4Chief Digital and Technology Officer; research head leads research AINot publishedLittle publishedAI share of research decisions, no value$729k
Sanofi4 of 4Chief Digital OfficerLevel 1, about 80% useRAISE framework, five pillarsResults by use case, no total$644k

Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. See all companies in the AI Strategy Index.

Frequently Asked Questions

What is AstraZeneca’s AI strategy for its own work?

AstraZeneca is building AI skills across its workforce and running about 1,000 pilots, with finance deciding which ones scale. It is also adding AI to oncology research through the Modella AI acquisition.

‍

How does AstraZeneca certify employees in AI?

AstraZeneca uses a Bronze, Silver and Gold framework. More than 17,000 employees were certified by April 2026, and staff above a certain grade must reach at least Silver.

‍

Who leads AI at AstraZeneca?

The sources reviewed name no single AI owner. Chief Financial Officer Aradhana Sarin described the certification program and the review of pilots in 2026.

‍

Is AstraZeneca cutting jobs because of AI?

AstraZeneca does not expect AI to lead to staff reductions, Sarin said in July 2026. Headcount rose to about 96,100 at the end of 2025.

‍

How is this profile put together?

Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.

About the AI Strategy Index

The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.

See all company profiles